IN2013MU02911A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02911A
IN2013MU02911A IN2911MU2013A IN2013MU02911A IN 2013MU02911 A IN2013MU02911 A IN 2013MU02911A IN 2911MU2013 A IN2911MU2013 A IN 2911MU2013A IN 2013MU02911 A IN2013MU02911 A IN 2013MU02911A
Authority
IN
India
Prior art keywords
relates
pharmaceutical compositions
sodium picosulfate
citric acid
magnesium oxide
Prior art date
Application number
Other languages
English (en)
Inventor
Muthaiyyan Essakimuthu Kannan
Jitendra Rameshchandra Patel
Paritosh Kunwar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2911MU2013 priority Critical patent/IN2013MU02911A/en
Priority to US14/482,678 priority patent/US20150072014A1/en
Publication of IN2013MU02911A publication Critical patent/IN2013MU02911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
IN2911MU2013 2013-09-10 2013-09-10 IN2013MU02911A (hr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2911MU2013 IN2013MU02911A (hr) 2013-09-10 2013-09-10
US14/482,678 US20150072014A1 (en) 2013-09-10 2014-09-10 Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2911MU2013 IN2013MU02911A (hr) 2013-09-10 2013-09-10

Publications (1)

Publication Number Publication Date
IN2013MU02911A true IN2013MU02911A (hr) 2015-07-03

Family

ID=52625867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2911MU2013 IN2013MU02911A (hr) 2013-09-10 2013-09-10

Country Status (2)

Country Link
US (1) US20150072014A1 (hr)
IN (1) IN2013MU02911A (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
US20160220492A1 (en) * 2015-01-31 2016-08-04 Gavis Pharmaceuticals Pharmaceutical composition of sodium picosulfate
EP3337513A1 (en) * 2015-08-17 2018-06-27 Ferring B.V. Liquid formulations containing picosulfate and magnesium citrate
CN105456264B (zh) * 2015-12-03 2018-07-10 广州瑞尔医药科技有限公司 双效缓泻的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011024A1 (en) * 1993-10-19 1995-04-27 The Procter & Gamble Company Picosulphate dosage form
US8481083B2 (en) * 2007-10-12 2013-07-09 Ferring International Center S.A. Granular compositions of magnesium oxide and citric acid and uses thereof
DK2877163T3 (en) * 2012-07-27 2019-04-15 Redhill Biopharma Ltd FORMULATIONS AND PROCEDURES FOR THE PREPARATION OF FORMS FOR USING GAS DRAINAGE

Also Published As

Publication number Publication date
US20150072014A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX366899B (es) Nuevos compuestos.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
PH12014501991B1 (en) Phenicol antibacterials
IN2015DN03327A (hr)
IN2013MU03583A (hr)
TN2012000457A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
PL2841549T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2841548T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2961822T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
IN2013MU03373A (hr)
IN2013MU02911A (hr)
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
PL2989192T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
GB2527233A (en) Composition comprising hydrocortisone
MY168952A (en) Fe (iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias